MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual...
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday,...
MD Anderson, UT Austin Announce First Collaborative Projects in...
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is...
MD Anderson and Allogene Therapeutics announce strategic...
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration...
Dual checkpoint blockade promising as pre-surgical approach for...
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab...
Study finds cancer mutations accumulate in distinct regions...
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do...
Next-gen bioinformatics tool enables big data analysis...
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
MD Anderson and Taiho Pharmaceutical announce collaboration...
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for...
KRAS inhibitor sotorasib appears safe, achieves durable...
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C...
MD Anderson and Xencor enter strategic collaboration to...
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study...
Lung cancer trial of RET inhibitor selpercatinib achieves...
For patients with non-small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well...
Targeted therapy combination effective for patients with...
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF...
Study shows frequently used serology test may not detect...
Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to...
Cancer care and screenings must remain a priority during...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the...
Implementation of social distancing policies correlates...
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies...
MD Anderson honored to rank as nation’s best hospital for...
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020...
MD Anderson and Sanofi announce strategic collaboration to...
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the...
MD Anderson and UT Austin Create Unique Data-Driven Collaboration...
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for...
Study shows sedentary behavior independently predicts...
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas...
Combination biomarker predicts response to immune...
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved...
MD Anderson and Philips collaborate to facilitate personalized...
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with...
MD Anderson and Rakuten Medical announce strategic alliance to...
The University of Texas MD Anderson Cancer Center and Rakuten Medical, Inc. today announced a strategic alliance collaboration...
Statement from Peter WT Pisters, M.D., regarding the tragic death...
At MD Anderson, we are filled with anguish and deep sorrow over the senseless acts of racism and violence in our country and the...
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows...
ABSTRACT: #102
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the...
Targeted therapy pralsetinib achieves high response rates...
ABSTRACT: #109
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad...
Targeted therapy tepotinib for non-small cell lung cancer...
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective...
Novel targeted drug induced positive response for patients...
ABSTRACT: #5003
In an international trial led by researchers at The University of Texas MD Anderson Cancer Center, treatment with...
MD Anderson and Innovent Biologics announce a strategic...
The University of Texas MD Anderson Cancer Center and Innovent Biologics, Inc. today announced a strategic collaboration agreement to...
MD Anderson, Ipsen advance new therapy with potential...
ABSTRACT: DDT01-03
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1),...
Majority of patients responded in CAR T-cell trial for...
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell...
Immunotherapy effective in metastatic prostate cancers with...
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients...
New therapeutic strategies proposed for some lung and...
New findings from researchers at The University of Texas MD Anderson Cancer Center about how some cancer cells become “addicted” to...
Combination creates powerful central memory T cells for...
Treating T cells harvested from a patient with a combination of an epigenetic drug and a cytokine while expanding the cells in the lab...
Study sheds light on fatty acid’s role in “chemobrain” and...
Medical experts have always known myelin, the protective coating of nerve cells, to be metabolically inert. A study led by The...
Pembrolizumab shows promise for some advanced,...
A study conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated acceptable toxicity and anti-tumor...
Osteosarcoma profiling reveals why immunotherapy remains...
Comprehensive profiling of tumor samples taken from patients with osteosarcoma shows that multiple factors contribute to the...
MD Anderson announces strategic collaboration with Denali...
The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to...
MD Anderson receives more than $20 million in CPRIT funding
The University of Texas MD Anderson Cancer Center today was awarded more than $20 million from the Cancer Prevention and Research...
Houston Dash join Dynamo, MD Anderson in Making Cancer...
The University of Texas MD Anderson Cancer Center today announced the Houston Dash will join the institution's efforts toward one...
Absent p53, oral cancers recruit and reprogram nerves to...
Loss of an important tumor-suppressing gene allows head and neck cancer to spin off signals to nearby nerves, changing their function...
CD19 CAR NK-cell therapy achieves 73% response rate in...
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived...
Study provides new understanding of mitochondria genome...
A study led by The University of Texas MD Anderson Cancer Center furthered understanding about mitochondria, the cell components known...
MD Anderson supports World Cancer Day through dedication to...
The University of Texas MD Anderson Cancer Center honors World Cancer Day, Feb. 4, as the campaign celebrates 20 years of bringing...
Craig Owen Named Chief Information Officer
The University of Texas MD Anderson Cancer Center today named Craig Owen as its chief information officer. Owen has served the...